Robert P. Giugliano

REDUCTION IN LIPOPROTEIN (A) WITH EVOLOCUMAB: ELUCIDATION OF THE ROLE OF THE LDL RECEPTOR FROM CLINICAL TRIALS AND IN-VITRO MODELS

Lp(a) is an independent risk factor for cardiovascular disease risk. Statins increase low-density lipoprotein receptor (LDLR) activity but have little effect on Lp(a), while the PCSK9-inhibitor evolocumab consistently reduces Lp(a) 20-30% by a yet unknown mechanism. We investigated the possible role

TWO YEAR ANALYSIS OF THE SAFETY AND TOLERABILITY OF EVOLOCUMAB: THE OSLER-1 STUDY

The OSLER-1 study previously reported that SC evolocumab, a monoclonal antibody against PCSK9, markedly lowered and maintained LDL-C levels with a favorable safety profile, over 52 weeks. We now evaluate the efficacy, safety and persistence of evolocumab treatment over ~2 years (y).nnOSLER

SAFETY OF VERY LOW LDL-C LEVELS WITH EVOLOCUMAB: AN ANALYSIS OF 5942 PATIENTS FROM PHASE 2 AND 3 AND OPEN-LABEL EXTENSION STUDIES

Evolocumab, a fully human monoclonal antibody to PCSK9, can reduce LDL-C to very low (VL) levels. We assessed the safety of VL LDL-C by analyzing data from a pooled analysis of patients in evolocumab phase 2 or 3 randomized and placebo/comparator-controlled trials and in open-label extension (OLE)